GlassScriptPhysician profile
Joseph B Porter
NPI 1720432495
$4,335.46
in general payments reported to CMS, 2019-2025
26 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $2,425 · 2023: $140 · 2024: $718 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,971.79 | 2022 | |
| Abbvie INC. | $838.19 | 2021-2025 | |
| Stryker Corporation | $302.97 | 2021-2025 | Reunion |
| Lilly USA, LLC | $204.68 | 2021-2023 | Emgality, Reyvow, Amyvid |
| Microtransponder, INC. | $139.84 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2021 | |
| Livanova USA, INC. | $77.60 | 2021 | |
| Avanir Pharmaceuticals, INC. | $75.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.31 | 2022 | |
| Neurocrine Biosciences, INC. | $58.72 | 2021 | |
| Emd Serono, INC. | $54.25 | 2023 | Mavenclad |
| Biogen, INC. | $48.35 | 2021 | |
| Eisai INC. | $40.70 | 2021 | |
| Adamas Pharmaceuticals, INC. | $35.55 | 2021 | |
| Avanos Medical | $35.26 | 2024 | Coolief* Cooled Radiofrequency |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $34.41 | 2024 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $33.67 | 2021 | |
| Skeletal Dynamics INC | $32.72 | 2024 | Align, Implate, Ijs |
| Acadia Pharmaceuticals INC | $29.91 | 2021 | |
| Allergan, INC. | $26.97 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.40 | 2021 | |
| Sk Life Science, INC. | $22.78 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.79 | 2022 | |
| Novo Nordisk INC | $15.07 | 2024 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $13.89 | 2025 | Dysport |
| Janssen Pharmaceuticals, INC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.